Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 24, 2022 16:01 ET | Source: Eledon Pharmaceuticals, Inc.

Eledon Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Operating and Financial Results

Topline data from Phase 2a trial of tegoprubart in ALS expected in 2Q 2022 Ongoing clinical studies evaluating tegoprubart in kidney transplantation, IgA nephropathy, and islet cell transplantation...
March 17, 2022 08:00 ET | Source: Eledon Pharmaceuticals, Inc.

Eledon Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 24, 2022

IRVINE, Calif., March 17, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of...
February 14, 2022 08:00 ET | Source: Eledon Pharmaceuticals, Inc.

Eledon Pharmaceuticals Provides Corporate Update and 2022 Outlook

Completed enrollment of all four cohorts in ongoing Phase 2a study with tegoprubart (AT-1501) in Amyotrophic Lateral Sclerosis (ALS) Announces USAN Approval of Generic Name “tegoprubart” for lead...
February 08, 2022 16:05 ET | Source: Eledon Pharmaceuticals, Inc.

Eledon Pharmaceuticals to Participate in 11th Annual SVB Leerink Global Healthcare Conference

IRVINE, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of...
December 27, 2021 17:17 ET | Source: Eledon Pharmaceuticals, Inc.

Eledon Pharmaceuticals to Participate in January 2022 Investor Conferences

IRVINE, Calif., Dec. 27, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of...
November 11, 2021 16:05 ET | Source: Eledon Pharmaceuticals, Inc.

Eledon Pharmaceuticals Reports Third Quarter 2021 Operating and Financial Results

Nearing full enrollment in ALS Phase 2 Study; topline data expected 1H 2022 Received Investigational New Drug (“IND”) clearance from the FDA for AT-1501 in islet cell transplantation in the U.S. ...
November 04, 2021 17:34 ET | Source: Eledon Pharmaceuticals, Inc.

Eledon Pharmaceuticals CEO David-Alexandre C. Gros, M.D., to Present at CareDx Virtual Transplant Innovation Day during ASN Kidney Week 2021

IRVINE, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for...
November 04, 2021 16:05 ET | Source: Eledon Pharmaceuticals, Inc.

Eledon Pharmaceuticals Announces Participation in November Conferences

IRVINE, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for...
November 01, 2021 08:00 ET | Source: Eledon Pharmaceuticals, Inc.

Eledon Pharmaceuticals to Release Third Quarter Financial Results on Thursday, November 11, 2021

IRVINE, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines...
October 07, 2021 07:51 ET | Source: Eledon Pharmaceuticals, Inc.

Eledon Pharmaceuticals Announces Presentation on AT-1501 at the Virtual 2021 Northeast Amyotrophic Lateral Sclerosis Consortium

IRVINE, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for...